Cysteine

Cysteine

SCHEMBL1848591

CC(N)=O.N[C@@H](CS)C(=O)O

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.80
SLC7A11 Q9UPY5 1/20 0.80
SLC7A5 Q01650 1/20 0.46
ENPEP Q07075 4/20 0.45
GRIK1 P39086 2/20 0.45
BLM P54132 3/20 0.44
KMT2A Q03164 2/20 0.44
ALOX15 P16050 2/20 0.44
PMP22 Q01453 1/20 0.44
NOS2 P35228 6/20 0.44
NOS1 P29475 4/20 0.44
NOS3 P29474 3/20 0.44
CYP2C19 P33261 2/20 0.44
MEN1 O00255 1/20 0.44
CYP1A2 P05177 3/20 0.42
TSHR P16473 2/20 0.42
CYP3A4 P08684 1/20 0.42
NFKB1 P19838 2/20 0.42
GLA P06280 1/20 0.42
APEX1 P27695 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cysteine SCHEMBL21747580 0.92 PTGS1 (0.84) PTGS1SLC7A11SLC7A5ENPEPGRIK1
Cysteine SCHEMBL27613026 0.92 PTGS1 (0.84) PTGS1SLC7A11SLC7A5ENPEPGRIK1
Cysteine SCHEMBL6244297 0.90 PTGS1 (0.80) PTGS1SLC7A11SLC7A5ENPEPGRIK1
Cysteine SCHEMBL1275659 0.90 PTGS1 (0.80) PTGS1SLC7A11SLC7A5ENPEPGRIK1
Cysteine SCHEMBL6112867 0.90 PTGS1 (0.80) PTGS1SLC7A11SLC7A5ENPEPGRIK1
Cysteine SCHEMBL28253736 0.90 PTGS1 (0.80) PTGS1SLC7A11SLC7A5ENPEPGRIK1
Cysteine SCHEMBL6244287 0.90 PTGS1 (0.80) PTGS1SLC7A11SLC7A5ENPEPGRIK1
Cysteine SCHEMBL6112869 0.90 PTGS1 (0.80) PTGS1SLC7A11SLC7A5ENPEPGRIK1
Cysteine SCHEMBL25292211 0.90 PTGS1 (0.89) PTGS1SLC7A11SLC7A5ENPEPGRIK1
Cysteine SCHEMBL11344868 0.90 PTGS1 (0.89) PTGS1SLC7A11SLC7A5ENPEPGRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481725-B2 Cycloalkylcarbonylamino acid derivative and process for producing the same SEIKAGAKU CORPORATION (JP) 2013-07-09 US disclosed
EP-1972636-B1 CYCLOALKYLCARBONYLAMINO ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME SEIKAGAKU KOGYO CO LTD (JP) 2011-05-25 EP disclosed
US-20090111983-A1 Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same SEIKAGAKU CORPORATION (JP) 2009-04-30 US disclosed
EP-1972636-A1 CYCLOALKYLCARBONYLAMINO ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME SEIKAGAKU CORPORATION (JP) 2008-09-24 EP disclosed
EP-1669351-A2 Method for preserving quaternary ammonium salt Tokuyama Corporation (JP) 2006-06-14 EP disclosed
EP-1178043-B1 METHOD FOR STORING QUATERNARY AMMONIUM SALT TOKUYAMA CORP (JP) 2005-12-28 EP disclosed
US-6852856-B2 Method for preserving quaternary ammonium salt TOKUYAMA CORPORATION (JP) 2005-02-08 US disclosed
EP-1085000-B1 PROCESS FOR PRODUCING CARBOXYLIC ACID DERIVATIVE AND CONDENSING AGENT COMPRISING QUATERNARY AMMONIUM SALT TOKUYAMA CORP (JP) 2004-10-06 EP disclosed
US-20040147740-A1 Method for storing quaternary ammonium salt HIRANO NAOKI (JP) 2004-07-29 US disclosed
US-20030153785-A1 Method for preserving quaternary ammonium salt TOKUYAMA CORPORATION (JP) 2003-08-14 US disclosed
US-6458948-B1 MIXING A QUATERNARY AMMONIUM SALT HAVING A PARTICULAR TRIAZINE RING IN THE MOLECULES THEREOF, A CARBOXYLIC ACID COMPOUND AND A COMPOUND HAVING A NUCLEOPHILIC FUNCTIONAL GROUP, TO CONDENSE THE CARBOXYLIC ACID WITH THE COMPOUND HAVING THE NUCLEOPHILIC TOKUYAMA CORPORATION (JP) 2002-10-01 US disclosed
EP-1178043-A1 METHOD FOR STORING QUATERNARY AMMONIUM SALT TOKUYAMA CORPORATION (JP) 2002-02-06 EP disclosed
EP-1085000-A1 PROCESS FOR PRODUCING CARBOXYLIC ACID DERIVATIVE AND CONDENSING AGENT COMPRISING QUATERNARY AMMONIUM SALT TOKUYAMA CORPORATION (JP) 2001-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153785-A1 Method for preserving quaternary ammonium salt NHERF1, ASH1L, ATP6V1B1 PTGS1 4669/4885SLC7A11 1440/4885SLC7A5 2282/4885
US-20040147740-A1 Method for storing quaternary ammonium salt ASNS, ATP1B2, SCN7A PTGS1 4609/4885SLC7A11 1078/4885SLC7A5 1250/4885
US-20090111983-A1 Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same CTSK, CTSS, CTSV PTGS1 2162/4885SLC7A11 369/4885SLC7A5 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.